Wall Street Zen cut shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.
A number of other brokerages also recently issued reports on UNCY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Guggenheim reissued a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Finally, Benchmark restated a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.25.
View Our Latest Stock Analysis on Unicycive Therapeutics
Unicycive Therapeutics Price Performance
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.41. As a group, equities research analysts expect that Unicycive Therapeutics will post -1.16 earnings per share for the current year.
Hedge Funds Weigh In On Unicycive Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of UNCY. Pinnacle Wealth Planning Services Inc. purchased a new stake in Unicycive Therapeutics during the third quarter valued at $36,000. Chicago Partners Investment Group LLC grew its position in Unicycive Therapeutics by 26.0% during the third quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after buying an additional 5,556 shares during the period. Renaissance Technologies LLC purchased a new stake in Unicycive Therapeutics during the first quarter valued at approximately $161,000. Bank of America Corp DE raised its position in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after acquiring an additional 29,378 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Unicycive Therapeutics during the 2nd quarter valued at $248,000. 40.42% of the stock is currently owned by hedge funds and other institutional investors.
About Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Further Reading
- Five stocks we like better than Unicycive Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
